Lupus 2011; 20: 1187–92 Cervera R, Khamashta MA, Font J, et al. SARS-CoV-2-Impfstoff erzeugt in Phase-1-Studie zu 100 % neutralisierende AntikörperBluttest erkennt Morbus Alzheimer bis zu 20 Jahre vor ersten kognitiven StörungenWenn die Patienten nicht ausbleiben sollen, sollte man med. Ann Rheum Dis 73(6):958–967Wandinger KP, Stangel M, Witte T et al (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren’s syndrome.

Lupus 2011; 20: 1187–92.Cervera R, Khamashta MA, Font J, et al. Heidelberg, Berlin, New York: Springer Verlag 2004; 53–9.Kleinert S, Feuchtenberger M, Tony HP: Systemischer Lupus erythematodes. : Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. S2k-Leitlinie Diagnostik und Therapie des kutanen Lupus erythematodes. Ann Rheum Dis 2012; 71: 1833–8 Gemeinsamer Bundes­aus­schuss: Dossier zur Nutzenbewertung gemäß §35a SGBV – Belimumab (Benlysta) Modul 1. www.g-ba.de/downloads/92– 975–94/ 2012–01–27_Modul1_Belimumab.pdf? Darüber hinaus soll die Leitlinie Kostenträgern und politischen Entscheidungsträgern zur Orientierung dienen.

: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. The European Working Party on Systemic Lupus Erythematosus. Arch Dermatol 2009; 145: 244–8.Sardy M, Ruzicka T, Kuhn A: Topical calcineurin inhibitors in cutaneous lupus erythematosus.

Deutsche Gesellschaft für Rheumatologie e.V.



Arthritis Rheum 1982; 25: 1271–7.Jimenez S, Cervera R, Ingelmo M, Font J: The epidemiology of cutaneous lupus erythematosus. Im Jahr 2020 wollen wir dafür einen besseren Beitrag leisten. Ann Rheum Dis 73(6):958–967Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Arthritis Rheum 2005; 52: 1473–80 Kasitanon N, Fine DM, Haas M, Magder LS, Petri M: Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Z Rheumatol 2009; 68: 6–90.Ruiz-Irastorza G, Khamashta MA: Hydroxychloroquine: the cornerstone of lupus therapy. S2k-Leitlinie Diagnostik und Therapie des kutanen Lupus erythematodes. London: BMJ Group 2012; 476–505.Fischer-Betz R, Schneider M: Früher Lupus erythematodes.

Part 1. If we consistently apply the current options, we will be able to further improve the life situation and quality of life of those affected even without newly approved drugs.Alexander T, Sarfert R, Klotsche J et al (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 76:554–561van Vollenhoven RF, Hahn BH, Tsokos GC et al (2018) Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lymphknotenvergrößerung. Ann Rheum Dis 64(11):1618–1623European Reference Network ERN ReCONNET European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases. Lupus 2013; 22: 1286–94.Swaak AJ, Nossent JC, Smeenk RJ: Prognostic factors in systemic lupus erythematosus. Der Lupus erythematodes hat viele Gesichter.

Lancet 392(10155):1330–1339van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

Der Lupus erythematodes (LE) ist eine entzündliche Autoimmunerkrankung, die durch klinisch heterogene Manifestationen verschiedener Organe charakterisiert ist.
Curr Opin Rheumatol 2013; 25: 616–22.Kuhn A, Ruland V, Bonsmann G: Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011; 65: e179–93.Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF: Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ziel der Leitlinie ist es, Entscheidungshilfe zur Behandlung des komplexen Krankheitsbildes zu sein.

guidelines) are needed that enrich the possibility to reach the target and improve the prognosis of patients suffering from SLE.Aringer M, Houssiau F, Gordon C et al (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. : The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Arthritis Care Res (hoboken) 70(3):428–438 (Mar)Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) American academy of ophthalmology. Anders; Praxis für Innere Medizin – Rheumatologie, München: Prof. Dr. med. Zen M, Iaccarino L, Gatto M et al (2015) Prolonged remission in Caucasian patients with SLE: prevalence and outcomes.